Russell Investments Group Ltd. Sells 74,985 Shares of GeneDx Holdings Corp. (NASDAQ:WGS)

Russell Investments Group Ltd. trimmed its position in GeneDx Holdings Corp. (NASDAQ:WGS - Free Report) by 41.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 105,413 shares of the company's stock after selling 74,985 shares during the quarter. Russell Investments Group Ltd. owned 0.38% of GeneDx worth $8,102,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also added to or reduced their stakes in WGS. William Blair Investment Management LLC purchased a new stake in GeneDx in the fourth quarter worth $51,496,000. Zweig DiMenna Associates LLC bought a new position in GeneDx in the fourth quarter worth about $23,788,000. Raymond James Financial Inc. purchased a new stake in GeneDx in the fourth quarter worth about $20,371,000. Vanguard Group Inc. boosted its position in GeneDx by 18.5% during the 4th quarter. Vanguard Group Inc. now owns 1,006,210 shares of the company's stock valued at $77,337,000 after acquiring an additional 156,768 shares in the last quarter. Finally, Wellington Management Group LLP purchased a new position in shares of GeneDx during the 4th quarter worth approximately $10,821,000. Institutional investors own 61.72% of the company's stock.

GeneDx Stock Down 2.9 %

NASDAQ WGS traded down $2.81 during mid-day trading on Friday, reaching $95.47. The stock had a trading volume of 621,673 shares, compared to its average volume of 680,626. The stock has a market cap of $2.68 billion, a PE ratio of -48.71 and a beta of 1.93. GeneDx Holdings Corp. has a 1 year low of $8.63 and a 1 year high of $115.60. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.40 and a quick ratio of 2.27. The company has a fifty day moving average price of $93.23 and a 200 day moving average price of $79.44.

GeneDx (NASDAQ:WGS - Get Free Report) last released its quarterly earnings data on Tuesday, February 18th. The company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.04 by $0.66. The company had revenue of $95.64 million during the quarter, compared to the consensus estimate of $82.24 million. GeneDx had a positive return on equity of 3.33% and a negative net margin of 17.12%. On average, research analysts expect that GeneDx Holdings Corp. will post 0.97 earnings per share for the current year.

Insider Buying and Selling at GeneDx

In other news, CFO Kevin Feeley sold 402 shares of GeneDx stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $90.05, for a total transaction of $36,200.10. Following the transaction, the chief financial officer now owns 5,044 shares in the company, valued at $454,212.20. This trade represents a 7.38 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Katherine Stueland sold 1,657 shares of the company's stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $78.48, for a total value of $130,041.36. Following the completion of the sale, the chief executive officer now owns 3,937 shares of the company's stock, valued at $308,975.76. This trade represents a 29.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 138,780 shares of company stock worth $12,907,437. Insiders own 27.30% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the company. TD Cowen lifted their price target on GeneDx from $75.00 to $118.00 and gave the company a "buy" rating in a research report on Tuesday, January 7th. The Goldman Sachs Group increased their price target on shares of GeneDx from $70.00 to $80.00 and gave the stock a "neutral" rating in a research note on Wednesday, February 19th. Three analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. According to data from MarketBeat, GeneDx has an average rating of "Moderate Buy" and a consensus price target of $72.33.

GeneDx Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.